'Disheartening to see some states complain about our Covaxin intentions'

It is quite disheartening to listen to some states complaining about Bharat Biotech's intentions regarding supply of COVID vaccine Covaxin, a top company official said on Wednesday.

Covaxin
Covaxin
Press Trust of India New Delhi
2 min read Last Updated : May 12 2021 | 3:33 PM IST

It is quite disheartening to listen to some states complaining about Bharat Biotech's intentions regarding supply of COVID vaccine Covaxin, a top company official said on Wednesday.

In a tweet, Bharat Biotech Joint Managing Director Suchitra Ella said the company has already dispatched Covaxin lots to 18 states on May 10.

"18 states have been covered though in smaller shipments. Quite disheartening to the teams to hear some states complaining about our intentions. 50 of our employees are off work due to covid, yet we continue to work under pandemic lockdowns 24x7 for U," she said in a tweet.

The Hyderabad-based firm is supplying Covaxin to 18 states, including Andhra Pradesh, Haryana, Odisha, Assam, Jammu & Kashmir, Tamil Nadu, Bihar, Jharkhand and Delhi. Other states are Chhattisgarh, Karnataka, Telangana, Tripura, Madhya Pradesh, Uttar Pradesh, Gujarat, Maharashtra and West Bengal.

Earlier in the day, Delhi Deputy Chief Minister Manish Sisodia said Bharat Biotech has informed the state government that it cannot provide "additional" Covaxin doses to the national capital.

The stock of Covaxin in Delhi has finished and as a result around 100 vaccination centres set up in 17 schools have been closed, he said.

"The Covaxin manufacturer has in a letter said that it cannot provide Delhi government vaccines due to unavailability, under instruction of concerned government official. It means that the central government is controlling supply of the vaccine," Sisodia said.

He also said the Centre should stop export of vaccines and share the vaccine formulae of the two manufacturers in the country with other companies for mass scale production.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusBharat BiotechCoronavirus Vaccine

First Published: May 12 2021 | 3:25 PM IST

Next Story